#ranibizumab — Public Fediverse posts

European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)

F. Hoffmann-La Roche Ltd By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is…
#Europe #EU #continuousdelivery #EuropeanCommission #EuropeanUnion #maculardegeneration #macularedema #Ophthalmology #PortDeliveryPlatform #ranibizumab #Roche #Susvimo #treatmentoptions #visionloss
https://www.europesays.com/europe/143300/

https://www.europesays.com/ch/134053/ European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD) #ContinuousDelivery #EuropeanCommission #EuropeanUnion #MacularDegeneration #MacularEdema #ophthalmology #PortDeliveryPlatform #ranibizumab #Roche #Susvimo #TreatmentOptions #VisionLoss

https://www.europesays.com/ch/127377/ Novartis enters into exclusive promotion and distribution agreement with Novartis Healthcare | Capital Market News #AntivascularEndothelialGrowthFactorTherapy #Biotechnology&MedicalResearch(NEC) #BreakthroughTherapy #CalvinAGrant #CancerTreatments #ClinicalMedicine #Genentech #Health #India #medicine #Novartis #NovartisHealthcare #NovartisIndia #Pharmaceuticals(NEC) #ranibizumab

https://www.europesays.com/ch/107780/ Roche’s Susvimo Gets EU Approval Recommendation for nAMD #CHMPRecommendation #ContinuousDrugDelivery #ophthalmology #ranibizumab #RHHBY #Roche #Susvimo #WetAMD

https://www.europesays.com/ch/107672/ CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD) #Archway #EuropeanMedicinesAgency #EuropeanUnion #EyeDiseases #EyeInjections #MacularDegeneration #MacularEdema #PortDeliveryPlatform #ranibizumab #Roche #Susvimo #TreatmentOptions

https://www.europesays.com/ch/107616/ CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD) #Archway #EuropeanMedicinesAgency #EuropeanUnion #EyeDiseases #EyeInjections #MacularDegeneration #MacularEdema #PortDeliveryPlatform #ranibizumab #Roche #Susvimo #TreatmentOptions

https://www.europesays.com/ch/60095/ Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026 #DiabeticMacularEdema #DME #MacularDegeneration #MacularEdema #ophthalmology #ranibizumab #RealWorldData #RetinalConditions #RetinalVeinOcclusion #Roche

https://www.europesays.com/ch/59698/ Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026 #DiabeticMacularEdema #DME #MacularDegeneration #MacularEdema #ophthalmology #ranibizumab #RealWorldData #RetinalConditions #RetinalVeinOcclusion #Roche

https://www.europesays.com/ch/59195/ Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026 #DiabeticMacularEdema #DME #MacularDegeneration #MacularEdema #ophthalmology #ranibizumab #RealWorldData #RetinalConditions #RetinalVeinOcclusion #Roche

Sight-saving drug to be offered to premature babies, announces NHS | The Independent
https://www.independent.co.uk/news/health/nhs-newborn-sight-retinopathy-drug-b2368855.html

#RetinopathyOfPrematurity
#ROP
#Retinopathy
#PrematureBabies
#Sight
#NHS
#LowBirthWeight
#Retina
#Ranibizumab
#VascularEndothelialGrowthFactor